New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:31 EDTCVMCEL-SCI receives approval to expand Phase III trial to U.K.
CEL-SCI Corporation announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted regulatory approval to begin the company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in the United Kingdom. The U.K. becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer. Further expansion of the trial is underway with a goal to have a total of about 100 clinical centers through 20 countries by the end of 2015. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
10:00 EDTCVMCEL-SCI says enrolled 29 patients in Phase 3 Multikine trial in January
CEL-SCI Corporation announced that during the month of January it has enrolled 29 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 697 as of January 31, 2016 in the Phase 3 study in head and neck cancer. The current study goal is to enroll 880 patients through approximately 100 clinical centers in over 20 countries. The Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care vs. subjects who are treated with SOC only.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use